Major firms forecast to suffer poor Q1 results

Published: 2011-04-18 07:00:00

Updated: 2011-04-18 07:00:00

Major Korean pharmaceutical companies are likely to see their first-quarter earnings worsen sharply, buffeted by dramatic changes in the business environment such as regulations by the government, conflicts among drug manufacturers, doctors and pharmacists and intense competition among generic drugs.

According to Kim Hae-yeon, analyst of Woori Investment and Securities, the combined sales an...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.